The effect of infliximab treatment on insulin resistance in patients with rheumatoid arthritis

Acta Clinica Belgica

Volumn 62, Issue 4, 2007, Pages 218-222

  Oguz, F M ^a   Oguz, A ^a   Uzunlulu, Mehmet ^a,b  

^a E itim ve Ara tirma Hastanesi   (Turkey)

^b Altaycesme Mahallesi   (Turkey)

Author keywords

Infliximab; Insulin resistance; Rheumatoid arthritis; Tumour necrosis factor alpha

Indexed keywords

FOLIC ACID; GLUCOSE; INFLIXIMAB; INSULIN; LEFLUNOMIDE; LIPID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE DURATION; DRUG INFUSION; EVALUATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTERNAL MEDICINE; LIPID BLOOD LEVEL; LONG TERM CARE; MALE; MODEL; OUTPATIENT DEPARTMENT; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; THERAPY EFFECT;

EID: 34547785053     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2007.035     Document Type: Article

References (25)

1. Kaplan MJ. Cardiovascular disease in rheumatoid arthritis. Curr Opin Rheumatol. 2006; 18: 289-97.
2. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Inflammation and endothelial dysfunction in rheumatoid arthritis. Clin Exp Rheumatol. 2006; 24: 115-7.
3. Dessein PH, Joffe BI, Stanwix AE. Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. J Rheumatol. 2003; 30: 1403-5.
4. Borst SE. The role of TNF-α in insulin resistance. Endocrine. 2004; 23: 177-82.
5. Lee YH, Pratley RE. The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep. 2005; 5: 70-5.
6. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab. 2000; 11: 212-7.
7. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993; 259: 87-91.
8. Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med. 2006; 166: 902-8.
9. St Clair EW. Infliximab treatment for rheumatic disease: clinical and radiological efficacy. Ann Rheum Dis. 2002; 61 Suppl 2: ii67-9.
10. Yazdani-Biuki B, Stelzi H, Brezinschek HP, et al. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab. Eur J Clin Invest. 2004; 34: 641-2.
11. Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. 2005; 64: 765-6.
12. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, et al. Anti-tumour necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006; 24: 83-6.
13. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31: 315-24.
14. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38: 44-8.
15. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995; 38: 727-35.
16. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity: application to type 2 diabetes. Diabetes Care. 1997; 20: 1744-66.
17. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA). Evaluation uses the computer program. Diabetes Care. 1998; 21: 2191-2.
18. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum. 2005; 35: 8-17.
19. Dominguez H, Storgaard H, Rask-Madsen C, et al. Metabolic and vascular effects of tumour necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res. 2005; 42: 517-25.
20. Gentile S, Guarino G, Bizzarro A, De Bellis A, Torella R. Infliximab does not interfere with insulin secretion, insulin resistance and production of GAD and islet cell antibodies in patients with Crohn's disease. Diabet Obes Metab. 2002; 4: 276-7.
21. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004; 351: 1106-18.
22. 2+ channel antagonists, and alpha-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes. 1995; 44: 665-71.
23. Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care. 1991; 14: 203-9.
24. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005; 365: 1415-28.
25. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. (Adult Treatment Panel III). JAMA. 2001; 285: 2486-97.